Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 01)
Sildenafil Citrate Powder, For Suspension
Product Images NDC 70771-1668
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 70771-1668). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 02)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 03)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 04)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 05)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 06)
This text appears to be a table displaying different dosages. It contains three columns and three rows. Column headings appear to be "High Dose," "Medium Dose," and "Low Dose." The data in the table appears to be numerical values ranging from 8 to 80. Details about what this table represents or is used for are not provided.*
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 07)
Figure 7 (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 08)
This text provides information on the effects of different drugs on sildenafil (a medication used to treat erectile dysfunction). It includes measurements of the drugs' AUC and Cmax and suggests whether or not dose adjustments are needed when these drugs are taken with sildenafil. The text also mentions a clinical study that found no added benefit of sildenafil when combined with bosentan therapy.*
Figure 8 (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 09)
This text lists out the interacting drug acenocoumarol with other drugs and their effect on INR AUC, INR Cmax, and BT. Some drugs require no dose adjustment, while others have a coadministration not recommended or benefit when added to therapy. The text includes fold change and 90% Cl data with a recommendation listed at the end.*
Figure 9 (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 10)
Figure 10 (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 11)
The text appears to be a medical report showing the results of a study on the effects of Placebo, Sidenafi and Sildenafil in patients with pulmonary arterial hypertension (PAH). The report includes data on baseline walk distance, PAH etiology, PH criteria for functional capacity, therapeutic class, gender, and age. The study measures the mean pulmonary arterial pressure, pulmonary vascular resistance, and placebo-corrected change in 6-minute walk distance. No clear conclusion can be drawn from the text as it lacks consistent formatting and many characters have been garbled by .*
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 12)
This appears to be a chart that shows the percentage of patients without a clinically worsening kvent (unclear what kvent is) over time, with one group receiving a placebo. The chart shows that at day 84, 100% of the treatment group had not experienced a worsening kvent, while only 14% of the placebo group had not experienced a worsening kvent. By day 112, the treatment group still had 100% without worsening, while the placebo group had increased to 56% without worsening.*
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 13)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 14)
This appears to be a list of components for a medical product. It includes a cap, syringe adaptor, and a bottle of sildenafil for oral suspension. The final two items are described as a barrel and plunger, which could be parts of a syringe or other delivery device.*
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 15)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 16)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 17)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 18)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 19)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 20)
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 21)
This is a description of a Sildenafil for Oral Suspension medication. Each mL of the suspension contains 10mg of Sildenafil when reconstituted with 90ml water. The medication should be stored at below 30°C (86°F) in the original package before reconstitution and after reconstitution; it should be stored below 30°C (86°F) or in the refrigerator at a temperature of 20 8°C (36° to 46°F). The unused portion should be discarded after 60 days of reconstitution. The recommended dosage information is available in the package insert. The medication bottle is child-resistant. The medication has a grape flavor and is manufactured by Cadia Healthcare Ltd., India.*
Image (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 22)
This is a description for Sildenafil oral suspension, grape-flavored, with each ml containing 10mg of Sildenafil citrate to be reconstituted with 90 ml of water. It is recommended to shake the bottle well before use, and dosage should be taken as directed by the prescription. It comes with an oral syringe and a press-in bottle adapter. Before reconstitution, it should be stored below 30°C in the original package to prevent moisture. After reconstitution, it can be stored below 30°C or in the refrigerator, while leftover portions must be discarded 60 days after reconstitution. This medication is produced by Cadia Healthcare Ltd, India.*
Figure (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 23)
The text describes instructions and information about Sildenafil for Oral Suspension. The suspension contains 10 mg of Sildenafil citrate in each mL when reconstituted with 90 mL of water. Each bottle, which contains 1.57 g or 112 mg of Sildenafil, has a child-resistant package. The recommended dosage is listed on the package insert. Before reconstitution, the medication should be stored below 30°C to protect it from moisture. After reconstitution, it can be stored below 30°C or in a refrigerator between 2-8°C for up to 60 days, but should not be frozen. The medication is grape flavored and manufactured by Cadia Healthcare Ltd in India.*
Figure (D3a63b9a 864a 4ca7 Be7e 04be061dbfa3 24)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
